AIM ImmunoTechAIM -12.18%33 Quick Ratio is 1.01 as of Mar. 2026, which is 62% below its 10-year median of 2.68. GuruFocus rates AIM with a GF Score™ of 33/100 and a GF Value™ of $2.69 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 1,413 Biotechnology companies, AIM ImmunoTech ranks worse than 80.47% on this metric.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. AIM ImmunoTech's quick ratio for the quarter that ended in Mar. 2026 was 1.01.
AIM ImmunoTech has a quick ratio of 1.01. It generally indicates good short-term financial strength.
The historical rank and industry rank for AIM ImmunoTech's Quick Ratio or its related term are showing as below:
AIM'
s Quick Ratio Range Over the Past 10 Years
Min: 0.1 Med: 2.68 Max: 74.61
Current: 1.01
During the past 13 years, AIM ImmunoTech's highest Quick Ratio was 74.61. The lowest was 0.10. And the median was 2.68.
AIM's Quick Ratio is ranked worse than 80.47% of 1413
companies
in the Biotechnology industry
Industry Median: 3.6
vs AIM: 1.01
AIM ImmunoTech (AMEX:AIM) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
AIM ImmunoTech Quick Ratio Related Terms
AIM ImmunoTech Quick Ratio Historical Data
* Premium members only.
The historical data trend for AIM ImmunoTech's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, AIM ImmunoTech's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AIM ImmunoTech Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, AIM ImmunoTech's Quick Ratio distribution charts can be found below:
* The bar in red indicates where AIM ImmunoTech's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
AIM ImmunoTech's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AIM ImmunoTech (AIM) has a Quick Ratio of 1.01 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on AIM ImmunoTech and its competitors. This is 62% below median its historical median of 2.68. Over the past decade, AIM ImmunoTech's Quick Ratio has ranged from 0.10 to 74.61. According to the industry distribution chart, AIM ImmunoTech ranks #1137 out of 1413 companies in the Biotechnology industry, placing it in the top 80.5%.
Is AIM ImmunoTech's Quick Ratio too high?
AIM ImmunoTech's current Quick Ratio of 1.01 is 62% below median its 10-year median of 2.68. Over the past 10 years, this metric has ranged from a low of 0.10 to a high of 74.61. The Biotechnology industry median Quick Ratio is 3.60. AIM ImmunoTech's value of 1.01 is 71.9% below this industry median. Based on the distribution chart, AIM ImmunoTech ranks #1137 out of 1413 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, AIM ImmunoTech has a GF Score™ of 33/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does AIM ImmunoTech's Quick Ratio compare to BGMS and FBLG?
According to the Biotechnology industry distribution chart, AIM ImmunoTech ranks #1137 out of 1413 companies for Quick Ratio. This places AIM ImmunoTech in the lower half of its industry. The industry median Quick Ratio is 3.60. AIM ImmunoTech's value of 1.01 is 71.9% below this benchmark. Historically, AIM ImmunoTech's own Quick Ratio has ranged from 0.10 to 74.61 over the past decade. While the company's 10-year median is 2.68 vs. the industry median of 3.60, AIM ImmunoTech has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.60, based on 1,413 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. AIM ImmunoTech's current Quick Ratio of 1.01 is 71.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on AIM ImmunoTech and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AIM ImmunoTech's current Quick Ratio is 1.01, which is 62% below median its own 10-year median of 2.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AIM ImmunoTech stock overvalued right now?
Based on GuruFocus' analysis, AIM ImmunoTech (AIM) is currently considered Possible Value Trap. The stock's GF Value™ is $2.69, compared to a current price of $0.31 — trading 88.4% below its estimated fair value. The current Quick Ratio is 1.01, which is 62% below median its 10-year median of 2.68 and 71.9% below the Biotechnology industry median of 3.60. AIM ImmunoTech's overall GF Score™ is 33/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For AIM ImmunoTech (AIM), the current Quick Ratio is 1.01 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is AIM ImmunoTech (AIM) Overvalued in 2026?
Based on GuruFocus' analysis, AIM ImmunoTech stock appears to be undervalued.
The current stock price of $0.31 is trading 88.4% below its estimated GF Value™ of $2.69.
GuruFocus considers AIM ImmunoTech to be Possible Value Trap.
Key valuation signals for AIM:
Quick Ratio: 1.01 (62% below median its 10-year median of 2.68)
GF Value™: $2.69 vs. price of $0.31 (88.4% below fair value)
Industry Position: 71.9% below the Biotechnology median (#1137 of 1413)
No single metric tells the full story. See the AIM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
AIM ImmunoTech Inc is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders, and to treat cancers for which there are currently inadequate or unmet therapies. Its flagship products are Ampligen (rintatolimod) and Alferon N Injection (Interferon alfa). Ampligen is a double-stranded RNA (dsRNA) molecule being developed for globally important cancers, viral diseases, and disorders of the immune system. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe Chronic Fatigue Syndrome (CFS).
33GF Score
Get the complete analysis for AIM
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AIM has been successfully added to your 
